Business Context and Reporting Period
This Form 8-K was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on July 22, 2014, reporting an event that occurred on July 17, 2014. The filing details the entry into a material definitive agreement regarding the company's securitization facility.
Key Financial Metrics and Liquidity
The filing focuses on liquidity and debt capacity rather than operating performance metrics such as revenue or profit.
- Securitization Facility Base Limit: $950 million.
- Seasonal Expansion Option: Additional $250 million available during December and March quarters, subject to bank approval.
- Amended Dilution Ratio: Increased from 4.25% to 5.75% to trigger an Amortization Event.
- Underlying Assets: Accounts receivables originated by AmerisourceBergen Drug Corporation (ABDC) for pharmaceutical sales and related services.
Material Changes
The primary material change is the execution of the Seventh Amendment to the Amended and Restated Receivables Purchase Agreement. This amendment modifies the terms of the existing securitization facility by raising the threshold for the Dilution Ratio necessary to trigger an Amortization Event. This change provides greater flexibility in managing the facility's liquidity requirements.
Outlook, Risks, and Management Commentary
The facility is intended to provide additional liquidity and funding for the ongoing business needs of the Registrant and its subsidiaries. AmerisourceBergen Corporation serves as the performance guarantor for ABDC's obligations as the originator and servicer. The filing does not contain specific forward-looking guidance on revenue or earnings, nor does it detail new risks beyond the standard operational context of the receivables facility.
Investor Verification Checklist
- Verify the total available liquidity under the securitization facility, including the base limit and seasonal expansion options.
- Confirm the impact of the increased Dilution Ratio (5.75%) on the company's ability to maintain the facility without triggering an Amortization Event.
- Review the full text of the Seventh Amendment (Exhibit 10.1) for any other covenants or conditions not summarized in the 8-K.
- Assess the company's reliance on this facility for working capital needs in the pharmaceutical distribution sector.